Sun Pharmaceutical Industries Ltd. benchmarking: Perfomance to industry peers

Financial

	Sun Pharma Inds.	Torrent Pharma	Cipla
Operational Metrics
Pharmaceuticals
Number of ANDA's Filed in USA	661.0 .	172.0 .	282.0 .
Number of ANDA's Approved By USFDA	542.0 .	132.0 .	228.0 .
Domestic Sales Growth - YoY	15.2 %	17.2 %	15.5 %
US DMF Filings	529.0 .	n/a	2472.0 .
US DMF Approval	401.0 .	n/a	n/a
R&D as a % of Total Sales	6.5 %	5.0 %	7.0 %
Financials
5 yr Average ROE	11.67 %	20.79 %	13.9 %
5yr average Equity Multiplier	1.33	2.16	1.25
5yr Average Asset Turnover Ratio	0.57	0.69	0.78
5yr Avg Net Profit Margin	15.4 %	13.95 %	14.31 %
Price to Book	5.02	15.98	3.22
P/E	35.81	63.11	23.31
5yr Avg Cash Conversion Cycle	-46.88 Days	-186.79 Days	-4.31 Days
Inventory Days	65.22 Days	54.98 Days	57.83 Days
Days Receivable	84.33 Days	40.18 Days	50.64 Days
Days Payable	175.41 Days	298.32 Days	105.99 Days
5yr Average Interest Coverage Ratio	44.12	7.38	53.73
5yr Avg ROCE	18.0 %	25.78 %	19.36 %
5yr Avg Operating Profit Margin	26.44 %	30.49 %	23.02 %
5 yr average Debt to Equity	0.06	0.66	0.03
5yr CAGR Net Profit	30.35 %	8.83 %	17.0 %
5yr Average Return on Assets	8.92 %	9.73 %	11.19 %
Shareholdings
Promoter Holding	54.48 %	68.31 %	29.21 %
Share Pledged by Promoters	0.97 %	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.0	-2.94 %	-4.4 %
Change in Mutual Fund Holding (3 Yrs)	-0.37 %	-1.4 %	5.12 %

Business

	Sun Pharma Inds.	Torrent Pharma	Cipla
Product Wise Break-Up	Product Wise Break-Up India Branded Generics 34.0 US Formulations 29.0 Emerging Market 19.0 Western Europe & Other Markets 14.0 Active Pharmaceutical Ingredient (API) 4.0 Domestic formulations 0 Contract Manf. 0 Brazil/Latam 0 Germany/Europe 0 New ventures 0 Pharmaceuticals 0	Product Wise Break-Up Western Europe & Other Markets 0 Brazil 8.98 Domestic Formulations 42.15 Active Pharmaceutical Ingredient (API) 0 Contract Manufacturing 6.15 Pharmaceuticals 0 Germany 13.15 India Branded Generics 0 US Formulations 20.71 Emerging Market 0 New ventures 0 Others 8.86	Product Wise Break-Up Western Europe & Other Markets 0 Brazil/Latam 0 Domestic formulations 0 Active Pharmaceutical Ingredient (API) 0 Contract Manf. 0 Pharmaceutical 94.65 Germany/Europe 0 India Branded Generics 0 US Formulations 0 Emerging Market 0 New ventures 5.35
Therapeutic Area Wise Break-Up - Domestic	Therapeutic Area Wise Break-Up - Domestic Central Nervous System (CNS) 20.0 Cardiac Science 17.0 Gastro Intestinal 14.0 Anti - Diabetes 9.0 Pain Management 7.0 Anti-Infective 6.0 Respiratory Systems 5.0 Vitamins / Minerals / Nutrients 5.0 Gynecology 4.0 Dermatology 4.0 Ophthalmology 3.0 Urology 3.0 Anti-infectives 0 Cardiac 0 Gastro Intestinal 0 Antivirals 0 Derma 0 Neuro /CNS 0 Gynaec. 0 Vitamins 0 Antineoplast 0 Opthal/Otologicals 0 Oncology 0 Anti Diabetic 0 Others 3.0	-	Therapeutic Area Wise Break-Up - Domestic Anti-Infective 0 Anti - Diabetes 5.5 Derma 3.5 Gynecology 0 Vitamins / Minerals / Nutrients 0 Pain Management 0 Urology 5.1 Anti-Infective 13.8 Central Nervous System (CNS) 4.5 Respiratory Systems 0 Antivirals 0 Vitamins 0 Gynaec. 0 Cardiac Science 0 Gastro Intestinal 5.5 Ophthalmology 2.6 Oncology 0 Cardiac Science 11.8 Anti - Diabetes 0 Ophthalmology 0 Central Nervous System (CNS) 0 Dermatology 0 Antineoplast 0 Others 47.7
Location Wise Break-Up	Location Wise Break-Up India 33.39 USA 32.68 Emerging Market 19.13 Rest of the World 14.8 Germany 0 Brazil 0 SAGA 0 Europe 0 Global API 0 North America 0	Location Wise Break-Up North America 0 Europe 0 Rest of the World 0 Brazil 6.86 Germany 9.69 USA 9.69 India 56.99 Emerging Market 0 Global API 0 SAGA 0 Others 16.77	Location Wise Break-Up North America 21.0 Europe 13.0 Rest of the World 0 Brazil 0 Germany 0 USA 0 India 49.0 Emerging Market 0 Global API 2.0 SAGA 14.0 Others 1.0

Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Ltd.

Financial

Business

SIGN UP FOR FREE